Trial Profile
First-in-Human, Dose Finding, Open Label Phase 1A-1B Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Treatment-Refractory Solid Tumor Malignancies
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 13 Jul 2021
Price :
$35
*
At a glance
- Drugs NP G2 044 (Primary)
- Indications Advanced breast cancer; Colon cancer; Fallopian tube cancer; Liver cancer; Lung cancer; Lymphoma; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Prostate cancer; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Novita Pharmaceuticals
- 08 Jun 2021 Results presented at the 57th Annual Meeting of the American Society of Clinical Oncology
- 21 Dec 2020 Status changed from recruiting to completed.
- 19 Aug 2019 Planned End Date changed from 1 Dec 2019 to 1 Sep 2020.